OBJECTIVE: Cisplatin-refractory germ cell tumors (GCTs) represent a subset of germinal neoplasms with a poor prognosis. Conventional-dose chemotherapy induces objective response in 10-20% of these patients with rare durable complete remissions. We investigated the activity and tolerance of a chemotherapeutic regimen with oxaliplatin and gemcitabine. PATIENTS AND METHODS: Treatment consisted of oxaliplatin 130 mg/m(2) day 1, and gemcitabine 1,250 mg/m(2), days 1 and 8, every three weeks. RESULTS: Eighteen patients were enrolled and were assessable for response and toxicity. Primary site was testis in twelve cases, retroperitoneum in four, and mediastinum in two. Seven patients (39%) were cisplatin-refractory, while eleven (61%) absolutely cisplatin-refractory. A median of three cycles (range, 1-6) per patient were given. One patient achieved a clinical complete remission, one a partial remission with negative marker in whom complete surgical resection of residual masses yielded mature teratoma only, and one a partial remission with positive marker in whom complete surgical resection of residual masses yielded viable tumor cells. These three cases were characterized by testicular primary embryonal carcinoma. They remained disease-free at 44+, 20+, and 18+ months of follow-up. CONCLUSION: The oxaliplatin-gemcitabine combination is a safe and active standard-dose regimen for patients with cisplatin-refractory testicular primary GCT.
OBJECTIVE:Cisplatin-refractory germ cell tumors (GCTs) represent a subset of germinal neoplasms with a poor prognosis. Conventional-dose chemotherapy induces objective response in 10-20% of these patients with rare durable complete remissions. We investigated the activity and tolerance of a chemotherapeutic regimen with oxaliplatin and gemcitabine. PATIENTS AND METHODS: Treatment consisted of oxaliplatin 130 mg/m(2) day 1, and gemcitabine 1,250 mg/m(2), days 1 and 8, every three weeks. RESULTS: Eighteen patients were enrolled and were assessable for response and toxicity. Primary site was testis in twelve cases, retroperitoneum in four, and mediastinum in two. Seven patients (39%) were cisplatin-refractory, while eleven (61%) absolutely cisplatin-refractory. A median of three cycles (range, 1-6) per patient were given. One patient achieved a clinical complete remission, one a partial remission with negative marker in whom complete surgical resection of residual masses yielded mature teratoma only, and one a partial remission with positive marker in whom complete surgical resection of residual masses yielded viable tumor cells. These three cases were characterized by testicular primary embryonal carcinoma. They remained disease-free at 44+, 20+, and 18+ months of follow-up. CONCLUSION: The oxaliplatin-gemcitabine combination is a safe and active standard-dose regimen for patients with cisplatin-refractory testicular primary GCT.
Authors: Darren R Feldman; Lawrence H Einhorn; David I Quinn; Yohann Loriot; Johnathan K Joffe; David J Vaughn; Aude Fléchon; Julio Hajdenberg; Abdel-Baset Halim; Hamim Zahir; Robert J Motzer Journal: Invest New Drugs Date: 2013-02-17 Impact factor: 3.850
Authors: Silvia De Padova; Chiara Casadei; Alejandra Berardi; Tatiana Bertelli; Alessia Filograna; Maria Concetta Cursano; Cecilia Menna; Salvatore Luca Burgio; Amelia Altavilla; Giuseppe Schepisi; Sabrina Prati; Sandra Montalti; Michal Chovanec; Giuseppe Luigi Banna; Luigi Grassi; Michal Mego; Ugo De Giorgi Journal: Front Endocrinol (Lausanne) Date: 2019-05-28 Impact factor: 5.555
Authors: Giuseppe Schepisi; Silvia De Padova; Delia De Lisi; Chiara Casadei; Elena Meggiolaro; Federica Ruffilli; Giovanni Rosti; Cristian Lolli; Giorgia Ravaglia; Vincenza Conteduca; Alberto Farolfi; Luigi Grassi; Ugo De Giorgi Journal: Front Endocrinol (Lausanne) Date: 2019-02-25 Impact factor: 5.555
Authors: Isabel Blancas; Nuria Cárdenas; Mayte Delgado; Jose Miguel Jurado; Marta Legeren; Ana Villaescusa; Fernando Galvez; Marisol Yelamos Journal: Oncol Lett Date: 2014-09-10 Impact factor: 2.967